Literature DB >> 11163816

Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS.

M D Kahsar-Miller1, C Nixon, L R Boots, R C Go, R Azziz.   

Abstract

OBJECTIVE: To determine the rate of clinically evident polycystic ovary syndrome (PCOS) among first-degree female relatives within families with a proband affected by PCOS.
DESIGN: Clinical and biochemical evaluation of the mothers and sisters of 93 patients with PCOS. The diagnosis of PCOS was established by: [1] a history of oligomenorrhea, [2] clinical evidence (i.e., hirsutism) or biochemical evidence (i.e., elevated total or free T) of hyperandrogenism, and [3] the exclusion of related disorders.
SETTING: Tertiary care university. PATIENT(S): Patients with PCOS and their mothers and sisters. INTERVENTION(S): Interview, physical examination, and hormonal testing on blood samples were performed for all subjects. MAIN OUTCOME MEASURE(S): The presence of hirsutism and hyperandrogenemia was determined in the mothers and sisters of the patients with PCOS. RESULT(S): Of the 78 mothers and 50 sisters evaluated clinically, 19 (24%) and 16 (32%) were affected with PCOS, respectively. A higher rate of PCOS was observed when only premenopausal women not taking hormones (i.e., untreated) were considered (i.e., 35% of mothers and 40% of sisters), consistent with amelioration of symptoms with hormonal therapy or aging. These rates of PCOS are significantly higher than that observed in our general population (approximately 4%) and suggest the involvement of a major genetic component in the disorder. CONCLUSION(S): The rates of PCOS in mothers and sisters of patients with PCOS were 24% and 32%, respectively, although the risk was higher when considering untreated premenopausal women only.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11163816     DOI: 10.1016/s0015-0282(00)01662-9

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  76 in total

1.  Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome.

Authors:  Susan Sam; Richard S Legro; Paulina A Essah; Teimuraz Apridonidze; Andrea Dunaif
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-21       Impact factor: 11.205

Review 2.  Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: biobehavioral mechanisms and interventions.

Authors:  Kristen Farrell; Michael H Antoni
Journal:  Fertil Steril       Date:  2010-05-14       Impact factor: 7.329

Review 3.  The role of genes and environment in the etiology of PCOS.

Authors:  Evanthia Diamanti-Kandarakis; Helen Kandarakis; Richard S Legro
Journal:  Endocrine       Date:  2006-08       Impact factor: 3.633

4.  Polycystic ovary syndrome (PCOS): metformin.

Authors:  David J Cahill; Katherine O'Brien
Journal:  BMJ Clin Evid       Date:  2015-03-27

Review 5.  Ontogeny of polycystic ovary syndrome and insulin resistance in utero and early childhood.

Authors:  David H Abbott; Fida Bacha
Journal:  Fertil Steril       Date:  2013-07       Impact factor: 7.329

Review 6.  Polycystic ovary syndrome in adolescence.

Authors:  Colleen Buggs; Robert L Rosenfield
Journal:  Endocrinol Metab Clin North Am       Date:  2005-09       Impact factor: 4.741

Review 7.  PCOS.

Authors:  David Cahill
Journal:  BMJ Clin Evid       Date:  2009-01-15

Review 8.  The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.

Authors:  Robert L Rosenfield; David A Ehrmann
Journal:  Endocr Rev       Date:  2016-07-26       Impact factor: 19.871

9.  Evidence for association between polycystic ovary syndrome (PCOS) and TCF7L2 and glucose intolerance in women with PCOS and TCF7L2.

Authors:  Assel Biyasheva; Richard S Legro; Andrea Dunaif; Margrit Urbanek
Journal:  J Clin Endocrinol Metab       Date:  2009-04-07       Impact factor: 5.958

Review 10.  Genetic and environmental aspect of polycystic ovary syndrome.

Authors:  E Carmina
Journal:  J Endocrinol Invest       Date:  2003-11       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.